Novartis: Colorectal Neoplasms trials
The registry lists 30 Colorectal Neoplasms studies with Novartis as lead sponsor. 3 are open to participants now and 5 have results posted.
Phase 1 21Phase 2 8Phase 3 4Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsRecruitingNCT07630961Phase 1
- Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsRecruitingNCT07261631Phase 1
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruitingNCT06562192Phase 1
- Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRCTerminatedNCT04952753Phase 2Results posted
- [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)TerminatedNCT03724253Phase 2Results posted
- BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)CompletedNCT01750918Phase 1/2Results posted
- Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced DiarrheaCompletedNCT00582426Phase 3Results posted
- Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and ChemotherapyCompletedNCT00419159Phase 2Results posted
- Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsActive, not recruitingNCT07468071Phase 1/2
- Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.Active, not recruitingNCT05838768Phase 1
- A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
- Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationTerminatedNCT05358249Phase 1/2
- Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruitingNCT04699188Phase 1/2
- A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal CancerTerminatedNCT04294160Phase 1
- Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesTerminatedNCT04000529Phase 1
- Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal CancersCompletedNCT03798626Phase 1
- PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal CancerTerminatedNCT03176264Phase 1
- Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT03081494Phase 1
- Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02947165Phase 1
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
- Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid TumorsTerminatedNCT02703571Phase 1
- Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab TherapyTerminatedNCT02205398Phase 1
- Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsCompletedNCT01576666Phase 1
- A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal CancerCompletedNCT00478634Phase 1
- Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.CompletedNCT00056459Phase 3
- Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT00056446Phase 3
- STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced DiarrheaCompletedNCT00050635Phase 4
- EPO906 Therapy in Patients With Advanced Colorectal CancerCompletedNCT00035087Phase 2
- Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon CancerTerminatedNCT00006269Phase 3